Filana Therapeutics, Inc. (FLNA) vs Nephros, Inc. (NEPH)

A side-by-side comparison of Filana Therapeutics, Inc. and Nephros, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare

Total return — FLNA vs NEPH

growth of $100 · dividends reinvested · last 1y
FLNA -57.6% (-57.6%/yr)NEPH -5.6% (-5.6%/yr)NEPH compounded faster over this window
406080100120Start $100$42$94
FLNA NEPH

FLNA vs NEPH: by the numbers

  • •FLNA is the larger company ($42M vs $40M market cap).
  • •NEPH is profitable (8.38% net margin) while FLNA runs a net loss (0.00%).

Metrics side by side

Valuation

MetricFLNANEPH
P/E ratioN/A23.25
Forward P/EN/A23.55
P/S ratioN/A1.93
P/B ratio0.653.35
EV / EBITDAN/A20.53

Profitability

MetricFLNANEPH
Gross margin0.00%60.31%
Operating margin0.00%7.92%
Net margin0.00%8.38%
ROE-66.47%14.51%
ROIC-72.12%12.67%

Growth (annualized)

MetricFLNANEPH
Revenue CAGR (5Y)N/A16.99%
Total return CAGR (5Y)N/A-15.93%

Frequently asked

Is FLNA or NEPH more profitable?
NEPH runs the higher net margin — FLNA at 0.00% versus NEPH at 8.38%.

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.